Posted inHematology-Oncology news Respiratory

Immunosuppression and Long-term Survival After Single Living-donor Lobar Lung Transplantation from the Same Donor as Prior Hematopoietic Stem Cell Transplantation: An All-Japan Case Series

This case series examines immunosuppressive management and long-term outcomes in nine Japanese patients undergoing single living-donor lobar lung transplantation from the same donor as prior HSCT, revealing viable reduced immunosuppression and favorable survival.
Impact of Conditioning Regimens on Pregnancy Outcomes in Female Survivors of Childhood and Adolescent Acute Leukemia: HSCT versus Conventional Chemotherapy
Posted inHematology-Oncology news OB/GYN & Women's Health

Impact of Conditioning Regimens on Pregnancy Outcomes in Female Survivors of Childhood and Adolescent Acute Leukemia: HSCT versus Conventional Chemotherapy

This multicenter study reveals that total-body irradiation (TBI) conditioning before hematopoietic stem cell transplantation severely compromises pregnancy outcomes compared to alkylating agents or conventional chemotherapy in female survivors of childhood/adolescent acute leukemia.
Non‑conditioned Autologous Gene Therapy Reverses Bone Marrow Failure in Fanconi Anaemia‑A: FANCOLEN‑1 Phase 1/2 and Long‑Term Outcomes
Posted inHematology-Oncology news

Non‑conditioned Autologous Gene Therapy Reverses Bone Marrow Failure in Fanconi Anaemia‑A: FANCOLEN‑1 Phase 1/2 and Long‑Term Outcomes

The FANCOLEN‑1 trial shows that infusion of autologous FANCA‑corrected CD34+ cells without cytotoxic conditioning produced sustained engraftment and clinical improvement in a majority of treated patients with Fanconi anaemia‑A, with an acceptable short‑term safety profile and no genotoxicity detected during follow‑up.
Improving Outcomes in Mismatched Unrelated Donor Stem Cell Transplants With Post-Transplant Cyclophosphamide
Posted inClinical Updates Hematology-Oncology news Specialties Transplantation

Improving Outcomes in Mismatched Unrelated Donor Stem Cell Transplants With Post-Transplant Cyclophosphamide

Post-transplant cyclophosphamide (PTCy) for graft-versus-host disease prophylaxis significantly improves 1-year survival and lowers severe GVHD rates in mismatched unrelated donor peripheral blood stem cell transplants, expanding access for underrepresented patient groups.